UNSPSC 51182072: Testosterone heptanoate

This classification denotes an androgen with the molecular formula C26H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z6522T8N9, chemically known as androst-4-en-3-one, 17-(1-oxoheptyl)oxy-, (17.beta.)-, but more generally known as testosterone heptanoate, which bears US NIH Compound Identifier 9416. European Medicines Agency schedules testosterone heptanoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG.

Most nations, for tariff purposes, schedule testosterone heptanoate under HS 29372900. SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.

UNSPSC 51182072 Testosterone heptanoate is a Commodity code covering synthetic hormone pharmaceutical products sourced through state and local government cooperative purchasing agreements. State and local governments buy testosterone heptanoate as part of broader multi-source generic pharmaceutical procurement vehicles that bundle hormones, endocrine medications, and other controlled therapeutics for distribution across public health facilities, correctional institutions, and social-service agencies. The issuing bodies include state health departments and multistate cooperative purchasing alliances administering shared pharmaceutical contracts on behalf of participating state and local facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a primary buying vehicle in this space, using RFPs to consolidate demand across multiple jurisdictions and negotiating volume pricing with manufacturers and authorized pharmaceutical wholesalers.

Recent activity shows concentration in multistate cooperative purchasing frameworks rather than individual state or local solicitations. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with participating members including Oregon and other states; testosterone heptanoate falls within the pharmaceutical scope of this and similar MMCAP procurements. Vendors must comply with cGMP and Drug Supply Chain Security Act (DSCSA) certification, maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and accept 3 percent administrative fees. Awarded contracts effective July 1, 2026, run two years for new responders with optional extensions, while performance penalties for late reporting or missed onboarding range from $200 to $1,500 per violation.